• 미생물학회지
• /
• 제27권1호
• /
• pp.10-15
• /
• 1989

Mammalian cell 연구에 쓰기 위해 개발된 SV 40 transcriptional promoter를 함유하는 pKOneo plasmid를 발암 유전인자 연구에 쓰이는 NIH3T3 쥐 세포에 stable transfection 시켜 7개의 sub clones 얻었으며, 이 subclones이 갖는 세포 형질전환에 관한 여러가지 성질을 조사하였다. 실험결과에 따르면 stable transfection 후 세포 염색체에 삽입된 pKOneo plasmid 자체만으로도 NIH3T3 세포의 형질전환을 크게 일으키는 것으로 사료되었다.

• 미생물학회지
• /
• 제25권3호
• /
• pp.165-172
• /
• 1987

An expression vector in a mammalian cell was constructed using the origin of replication (OR) and the promoters of SV40. The plasmid pSVOE was constructed by inserting SV40 DNA fragment (1, 118bp) containing SV40 OR and promoters into pBR322-1, and then a multiple cloning sequence was inserted at the immediate downstream of the late promoter of SV40 in the pSVOE vector. The plasmid was named pSVML. As a selection marker, thymidine kinase gene of herpes simplex virus with its promoter was inserted into EcoRI site of pSVML and the recombinant was named pSVML-TKp. To test the expression capacity of foreigen gene inserted at the multiple cloning site of pSVML, the thymidine kinase gene without its own promoter was inserted at the BamHI site of pSVML. The recombinant was named pSVML-TK. These plasmids, pSVML-TKp and pSVML-TK, were transfected into COS cells with calcium phosphate precipitation method. The thymidine kinase activity was significantly increased in both transfected cells.

• Asian-Australasian Journal of Animal Sciences
• /
• 제8권5호
• /
• pp.449-454
• /
• 1995

The present study was conducted to assess gene expression of bacterial lacZ driven by the SV40 promoter at early developmental stages of bovine embryos. The lacZ gene was linearized with BamHI digestion and introduced into the pronucleus by microinjection at 20 hrs after the commencement of in vitro fertilization. Intact bovine blastocysts were not stained with X-Gal, suggesting that there is no endogenous beta-galactosidase activity in these blastocysts. In contrast, the bovine blastocyst cells microinjected with the lacZ gene exerted a characteristic greenish-blue color originating from the bacterial beta-galactosidase activity, albeit at a low rate, i.e. 2.1% of the total fertilized oocytes injected. It was concluded, therefore, that the lacZ gene driven by the SV40 promoter could be used for an indirect screening method in which the presence of transgene is evaluated from the product of transgene expression.

• 미생물학회지
• /
• 제27권2호
• /
• pp.85-91
• /
• 1989

조직특이적 및 일반적 유전자 발현에 미치는 SV40와 murine cytomegalovirus (MCMV) enhancer의 영향을 조사하였다. 이를 위하여 chloramphenicol acetyl transferase (CAT) 유전자의 아래쪽에 이들 enhancer들을 삽입한 재조합 플라스미드 들을 제조하였다. 원숭이세포(CV1PO)와 HeLa 세포에 이들 플라스미드들을 이입시킨 후, CAT 유전자가 발현되는 정도를 조사하였다. Enhancer가 없는 플라스미드에 비해 SV40와 MCMV enhancer는 CAT의 발현을 각각 20배와 150배로 가중시켰다. CAT 유전자의 앞에 있는 SV40 프로모터를 2.2kbp의 소성장호르몬(bGH) 유전자의 조절부위로 치환한 경우는 enhancer가 있어도 전혀 CAT 의 말현이 검출되지 않았다. 조절부위을 230 bp 로 짧게 하여 치환한 경우는, SV 40 enhancer 가 있을 때, CAT의 말현이 매우 증가하였다. 이와는 내조적으로 더 강한 MCMV enhancer는 bGH 특이적인 발현을 별로 증가시키지 못하였다.

• 한국동물학회지
• /
• 제28권3호
• /
• pp.166-178
• /
• 1985

한국형 B형 간염바이러스(HBV) DNA의 표면항원 유전자를 포유동물 세포에서 발현시켜 항원의 검출과 유전자의 분자유전학적인 연구를 하기 위하여 pre-surface antigen 지역과 표면항원 유전자 그리고 poly(A) addition site가 포함된 DNA 조각을 simian virus 40(SV 40)의 DNA 복제 원점과 promoter가 포함된 유전자 운반체에 재조함 시켰다. 우선, HBV DNA가 들어있는 pHBV 107을 Bam HI으로 부분절단한뒤 self-ligation시켜 두 HBV DNA가 같은 방향으로 들어간 pHBVD 107을 만들었다. 이 plasmid를 Bgl II로 절단하였을때 pre-surface지역과 표면항원 유전자 그리고 poly(A) addition site가 함께 포함된 2.7 kb의 insert DNA 조각을 얻었다. 유전자 운반체로는 포유동물세포에서 복제할 수 있도록 하기 위하여 SV40의 DNA 복제 원점부위와 72 bp repeats(enhancer)가 포함된 pSVOE를 만든다음 이 vector의 Pvu II 절단자리에 Bam HI linker를 붙여 insert DNA가 vector의 SV40 late promoter지역 가까이에 들어갈 수 있도록 변형시킨 pSVOB를 만들었다. 이상과 같이 만들어진 pre-surface 지역-표면항원유전자-poly(A)-addition site가 포함된 2.7 kb DNA 절편을 pSVOB promoter 뒤의 Bam HI site에 삽입하여 재조합된 plasmid pSVBS를 얻었다. 예비실험으로 pSVBS를 T-antigen이 생산되는 COS cell에 이주시켰더니 $HB_sAg$가 발현됨을 보았다.

• 한국동물학회지
• /
• 제37권2호
• /
• pp.137-143
• /
• 1994

Microiniection of genes Into Xenopus laeuis oocvtes in highly useful in the annvsis of gene regulation, since a large number of oocvtes can be injected in a relatively short time. The GRP78 enhancer has been identified to a 291-bp fragment that spans a region of GRP78 promoter between -378 and -87 (Lin et at., 1986: Kim and Lee, 1989). We examined whether this GRP78 enhancer is effective in directing expression of heterologous gene in Xenopus laeuis oocytes. The chloramphenicol acetvltransferase (CAT) fusion constructs containing the GRP78 promoter and the SV4O early promoter were constructed and were injected into nuclei of Xencpus laeuis oocvtes. The recipient oocvtes were then assayed for CAT activity. The fusion constructs exhibited higher activity as compared to SV40 promoter tested here. The GRP78 enhancer showed 8.5- to 9.2-fold enhancement over that of the SV4O promoter. The orientation of GRP78 enhancer with respect to the direction of CAT transcription unit had no significant effect. Thus, the GRP78 enhancer is a viable candidate for the construction of expression system for use in Xenopus laevss oocvtes and will be important for the studY of a gene expression throughout development.

• BMB Reports
• /
• 제29권2호
• /
• pp.156-162
• /
• 1996

Transcription of hepatitis B viral pregenomic promoter is known to be regulated mainly by the combined interaction of enhancers I, II and the intervening regulatory sequences between the two enhancers. A positive regulatory element was identified by serial deletion and measuring the linked chloramphenicol acetyltransferase (CAT) activities, which overlapped with the 5' region of the X open reading frame. When the positive regulatory element was inserted upstream of the SV40 early promoter, it elevated SV40 promoter activity in HepG2 cells. Two cellular proteins of 110 (p110) and 33 (p33) kDa interacted with the positive element and both of them were present in the nucleus, but p110 also existed in the cytoplasm in phosphorylated form. Dephosphorylation of p110 by acid phosphatase enhanced the DNA-binding activity of p110. The p33 could bind to single-strand DNA specifically as well as to double-strand DNA.

• 한국동물학회지
• /
• 제38권3호
• /
• pp.433-441
• /
• 1995

염소 베타-락토글로불린 유전자 프로모터의 유선 조직 특이성은, 비 발현 세포에서 -470 에서 -205 부위에 의해서 매개되는 억제 조절에 의해서 보증된다. 이 음성 조절 기작과 억제 조절을 매개하는 인자를 확인하기 위하여 상류 염기 서열을 자세히 분석하였다. 상류 염기 서열은 어느 방향으로 위치하든 연결된 베타-락토글로불린 유전자 프로모터의 활성을 억제할 수 있었다. 이와 같이 규명된 염소 베타-락토글로불린 유전자의 잠정적 음성 조절 인자는 다른 유전자의 프로모터들에 대해서는 다양한 활성을 보였는데, herpes simplex 바이러스의 thimidine kinase 프로모터는 상류 염기서열의 방향에 따라 억제 또는 활성화되었으며, SV40 프로모터는 억제되기보다는 오히려 활성화되었다. 염소 베타-락토글로불린 유전자의 억제 조절 인자를 포함하는 조절 부위는 비 유선 세포인 HeLa 및 CV-1 세포에서 추출된 핵 추출물에 의해서 이동성이 강력하게 지연되는 반면, 유선세포인 HC11 세포의 핵 추출물에 의해서는 약하게 지연되었다. 이와 같은 활성 억제와 인자 결합간의 연관성은 foot-printing 분석에서 관찰된 결합 부위가 염소의 베타-락토글로불린 유전자의 조직특이적 억제에 작용할 음성 조절 인자일 가능성을 시사한다.

• 한국동물번식학회:학술대회논문집
• /
• 한국동물번식학회 2001년도 춘계학술발표대회
• /
• pp.47-47
• /
• 2001

The neuropeptide vasopressin (VP) is a nine- amino acid hormone synthesized as preprohormone in the cell bodies of hypothalamic magnocellular neurons. The tumor in magnocellular neurons of the hypothalamus is associated with disfunctions of the cell bodies, leading to the diabetes insipidus. In order to study with the diabetes insipidus caused by a defect in VP synthesis and its secretion, we have produced the transgenic mice regulated by vasopressin promoter inserted to SV40 T antigen coding sequence (pVPSV.IGR2.1). One transgenic line expressing high levels of SV40 T antigen was propagated. The founder and all transgene positive adult animals have appeared with shorten mortality or apparent phenotypic abnormalities, including immune complex disease, and eventually die between 4 and 8 months of age. The mRNA and protein of SV40T antigen transgene were detected in brain of fetus as well as in brain, spleen, lung and lymph node in moribund at the age of 20 weeks. Histological analysis of transgenic mice showed that tumor developed in brain similar to primitive neuroectodermal tumors (PNET) in man. We also detected lymphomas in spleen and lymph node, and consequent tumor formation in various tissues of the transgenic mice. In pVPSV.IGR2.1, 21% mice showed brain tumor (PNET) at 5 weeks and 100% mice showed brain tumor after 15 weeks. In addition, Expression of apoptosis related genes (Bcl-28 & Bax) was increased over their age in mice with PNET as compared to control mice. Apoptosis related gene expression might be deregulated in mice with brain tumor. However, transgenic mice were not developed with the diabetes insipidus. These mice represent the first disease model to exhibit primitive neuroectodermal tumor in brain, as well as a unique model system for exploring the cellular pathogenesis of lymphomas.

• Bulletin of the Korean Chemical Society
• /
• 제30권4호
• /
• pp.897-901
• /
• 2009

Heme oxygenase-1 (HO-1) is an anti-inflammatory and anti-apoptotic protein and has been applied to various gene therapy researches. However, constitutive expression of HO-1 may induce deleterious side effects. In this research, hypoxia inducible HO-1 expression plasmid, pEpo-SV-HO-1, was constructed with the erythropoietin (epo) enhancer and simian virus 40 (SV40) promoter to avoid these unwanted side effects. Dexamethasone conjugated polyethylenimine (PEI-Dexa) was used as a gene carrier. It was previously reported that dexamethasone protected cardiomyocytes from apoptosis under hypoxia. In this research, PEI-Dexa reduced the caspase-3 level in hypoxic H9C2 cardiomyocytes as a derivative of dexamethasone, suggesting that PEI-Dexa is an anti-apoptotic reagent as well as a gene carrier. pEpo-SV-HO-1 was transfected to H9C2 cardiomyocytes using PEI-Dexa and the cells were incubated under normoxia or hypoxia. HO-1 expression was induced in the pEpo-SV-HO-1 transfected cells under hypoxia. In addition, cell viability under hypoxia was higher in the pEpo-SV-HO-1 transfected cells than the pEpo-SV-Luc transfected cells. Also, caspase-3 level was reduced in the pEpo-SV-HO-1 transfected cells under hypoxia. In addition to the anti-apoptotic effect of PEI-Dexa, hypoxia inducible HO-1 expression by pEpo-SVHO- 1 may be helpful to protect cardiomyocytes under hypoxia. Therefore, pEpo-SV-HO-1/PEI-Dexa complex may be useful for ischemic heart disease gene therapy.